• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

盐酸丁螺环酮缓释片体外-体内相关性的建立与验证

Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets.

作者信息

Takka Sevgi, Sakr Adel, Goldberg Arthur

机构信息

Industrial Pharmacy Program, University of Cincinnati, Medical Center, Cincinnati, OH, USA.

出版信息

J Control Release. 2003 Feb 14;88(1):147-57. doi: 10.1016/s0168-3659(02)00490-x.

DOI:10.1016/s0168-3659(02)00490-x
PMID:12586512
Abstract

The aim of this study was to develop an in-vitro-in-vivo correlation (IVIVC) for two buspirone hydrochloride extended release formulations and to compare their plasma concentrations over time with the commercially available immediate release (IR) tablets. In vitro release rate data were obtained for each formulation using the USP Apparatus 2, paddle stirrer at 50 and 100 rpm in 0.1 M HCl and pH 6.8 phosphate buffer. A three-way crossover study in 18 healthy subjects studied a 30 mg "Fast" (12 h) and 30 mg "Slow" (24 h) formulation of buspirone hydrochloride given once a day, and 2x15 mg immediate release tablets dosed at a 12 h interval. The similarity factor (f(2)) was used to analyze the dissolution data. A linear correlation model was developed using percent absorbed data and percent dissolved data from the two formulations. Predicted buspirone hydrochloride concentrations were obtained by use of a curve fitting equation for the immediate release data to determine the volume of distribution and fraction absorbed constants. Prediction errors were estimated for C(max) and area under the curve (AUC) to determine the validity of the correlation. pH 6.8 at 50 rpm was found to be the most discriminating dissolution method. Linear regression analyses of the mean percentage of dose absorbed versus the mean in vitro release resulted in a significant correlation (r(2)>0.95) for the two formulations. An average percent prediction error for C(max) was -0.16%, but was 16.1%, for the AUCs of the two formulations.

摘要

本研究的目的是建立两种盐酸丁螺环酮缓释制剂的体外-体内相关性(IVIVC),并将它们随时间变化的血浆浓度与市售速释(IR)片剂进行比较。使用美国药典装置2,在0.1 M盐酸和pH 6.8的磷酸盐缓冲液中,以50和100 rpm的转速用桨式搅拌器获得每种制剂的体外释放速率数据。在18名健康受试者中进行的一项三交叉研究,研究了每天服用一次的30 mg“快速”(12小时)和30 mg“慢速”(24小时)盐酸丁螺环酮制剂,以及以12小时间隔给药的2×15 mg速释片剂。相似性因子(f(2))用于分析溶出数据。使用两种制剂的吸收百分比数据和溶解百分比数据建立线性相关模型。通过对速释数据使用曲线拟合方程来确定分布容积和吸收分数常数,从而获得预测的盐酸丁螺环酮浓度。估计了C(max)和曲线下面积(AUC)的预测误差,以确定相关性的有效性。发现50 rpm时pH 6.8是最具区分性的溶出方法。对吸收剂量的平均百分比与平均体外释放进行线性回归分析,结果表明两种制剂具有显著相关性(r(2)>0.95)。两种制剂C(max)的平均预测误差百分比为-0.16%,但AUC的平均预测误差百分比为16.1%。

相似文献

1
Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets.盐酸丁螺环酮缓释片体外-体内相关性的建立与验证
J Control Release. 2003 Feb 14;88(1):147-57. doi: 10.1016/s0168-3659(02)00490-x.
2
In-vitro and in-vivo correlation for two gliclazide extended-release tablets.两种格列齐特缓释片的体外与体内相关性
J Pharm Pharmacol. 2007 Jul;59(7):971-6. doi: 10.1211/jpp.59.7.0009.
3
Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation.格列吡嗪缓释剂型:A级体外-体内相关性的开发与验证
Biol Pharm Bull. 2008 Oct;31(10):1946-51. doi: 10.1248/bpb.31.1946.
4
Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.开发用于维利帕尼(ABT-888)延长释放片剂制剂的 A 级体外-体内相关性。
Pharm Res. 2017 Jun;34(6):1187-1192. doi: 10.1007/s11095-017-2133-3. Epub 2017 Feb 27.
5
Pharmacokinetics of buspirone extended-release tablets: a single-dose study.丁螺环酮缓释片的药代动力学:一项单剂量研究。
J Clin Pharmacol. 2001 Jul;41(7):783-9. doi: 10.1177/00912700122010582.
6
Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation.亲水性酒石酸美托洛尔缓释片制剂的体外-体内相关性的建立与内部验证
Pharm Res. 1998 Mar;15(3):466-73. doi: 10.1023/a:1011988601696.
7
A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product.丁螺环酮缓释片与对照速释产品的多剂量药代动力学比较研究。
J Clin Pharmacol. 2001 Aug;41(8):886-94. doi: 10.1177/00912700122010681.
8
Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation.一种地尔硫䓬缓释制剂的非线性体内-体外相关性(IVIVC)模型的开发与验证
Biopharm Drug Dispos. 2002 Jan;23(1):1-8. doi: 10.1002/bdd.270.
9
Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.开发一种用于设计缓释口服剂型的具有生理相关性的群体药代动力学体外-体内相关性方法。
Mol Pharm. 2017 Jan 3;14(1):53-65. doi: 10.1021/acs.molpharmaceut.6b00677. Epub 2016 Dec 12.
10
In vitro-in vivo correlations for three different commercial immediate-release indapamide tablets.三种不同市售速释吲达帕胺片的体外-体内相关性
Drug Dev Ind Pharm. 2014 Dec;40(12):1670-6. doi: 10.3109/03639045.2013.842577. Epub 2013 Oct 8.

引用本文的文献

1
Response Surface Methodology for Optimization of Buspirone Hydrochloride-Loaded In Situ Gel for Pediatric Anxiety.响应面法优化盐酸丁螺环酮小儿焦虑症原位凝胶的研究
Gels. 2022 Jun 22;8(7):395. doi: 10.3390/gels8070395.
2
Development, Internal and External Validation of Naproxen Sodium Sustained Release Formulation: an Level A Correlation.萘普生钠缓释制剂的开发、内部和外部验证:A级相关性
Turk J Pharm Sci. 2017 Aug;14(2):120-126. doi: 10.4274/tjps.87587. Epub 2017 Aug 15.
3
Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers.
在健康男性志愿者中比较阿法骨化醇胆碱片与软胶囊的制剂及生物等效性研究。
Drug Des Devel Ther. 2019 Apr 5;13:1049-1058. doi: 10.2147/DDDT.S193424. eCollection 2019.
4
Dissolution method for delapril and manidipine combination tablets based on an absorption profile of manidipine.基于马尼地平吸收曲线的地拉普利与马尼地平复方片剂溶出度测定方法
J Pharm Anal. 2016 Feb;6(1):49-55. doi: 10.1016/j.jpha.2015.10.002. Epub 2015 Oct 23.
5
Convolution and validation of in vitro-in vivo correlation of water-insoluble sustained-release drug (domperidone) by first-order pharmacokinetic one-compartmental model fitting equation.采用一级药代动力学单室模型拟合方程对水不溶性缓释药物(多潘立酮)进行体外-体内相关性的卷积和验证。
Eur J Drug Metab Pharmacokinet. 2013 Sep;38(3):191-200. doi: 10.1007/s13318-012-0116-7. Epub 2012 Dec 23.
6
Improved bioavailability of poorly water-soluble drug curcumin in cellulose acetate solid dispersion.醋酸纤维素固体分散体提高难溶性药物姜黄素的生物利用度。
AAPS PharmSciTech. 2012 Mar;13(1):159-66. doi: 10.1208/s12249-011-9732-9. Epub 2011 Dec 16.
7
Preparation and in vitro/in vivo evaluation of microparticle formulations containing meloxicam.含美洛昔康的微粒制剂的制备及体外/体内评价。
AAPS PharmSciTech. 2012 Mar;13(1):46-52. doi: 10.1208/s12249-011-9718-7. Epub 2011 Nov 19.
8
A time scaling approach to develop an in vitro-in vivo correlation (IVIVC) model using a convolution-based technique.采用基于卷积的技术开发体外-体内相关性(IVIVC)模型的时间标度方法。
J Pharmacokinet Pharmacodyn. 2011 Oct;38(5):519-39. doi: 10.1007/s10928-011-9206-4. Epub 2011 Jul 7.
9
Real-time UV imaging of nicotine release from transdermal patch.实时紫外成像技术检测透皮贴片尼古丁释放情况
Pharm Res. 2010 Dec;27(12):2614-23. doi: 10.1007/s11095-010-0257-9. Epub 2010 Sep 2.
10
The science of USP 1 and 2 dissolution: present challenges and future relevance.美国药典1和2溶出度的科学:当前挑战与未来相关性
Pharm Res. 2009 Jun;26(6):1289-302. doi: 10.1007/s11095-008-9822-x. Epub 2009 Jan 23.